Direxion Daily LLY Bear 1X ETF (ELIS) Stock Analysis

Direxion Daily LLY Bear 1X ETF (ELIS) Financial Services Profile

The Direxion Daily LLY Bear 1X ETF (ELIS) offers investors inverse daily exposure to Eli Lilly and Company (LLY) common stock, aiming to mirror the opposite of LLY's daily performance by 100% before fees. It serves as a tactical instrument for short-term plays against LLY's share price movements.

What Is the Investment Thesis for ELIS?

The investment thesis for Direxion Daily LLY Bear 1X ETF (ELIS) centers on its utility as a tactical instrument for investors seeking inverse daily exposure to Eli Lilly and Company (LLY) common stock. With a stated objective to achieve daily returns mirroring the opposite movement of LLY's performance by 100% before fees, ELIS offers a direct mechanism to potentially profit from short-term declines in LLY's share price. Its market capitalization is $0.00B, indicating a niche product rather than a broad market fund. The fund's beta of 0.20, while seemingly low, must be interpreted in the context of its inverse and daily rebalancing nature, as its correlation to the broader market is less relevant than its inverse correlation to LLY. A primary value driver is the ability for investors to implement bearish strategies against LLY without engaging in short selling, which can involve margin requirements and specific borrowing costs. Growth catalysts for ELIS would primarily stem from increased bearish sentiment or negative news surrounding Eli Lilly, driving demand for inverse exposure. Conversely, a significant risk factor is the inherent effect of compounding over periods longer than one day, which can lead to performance deviations and potentially substantial losses, even if LLY's stock ultimately declines. Therefore, ELIS is best suited for highly active traders with a clear understanding of its daily rebalancing mechanism and the volatility of the underlying LLY stock.

Based on FMP financials and quantitative analysis

ELIS Key Highlights

Provides 100% inverse daily exposure to Eli Lilly and Company (LLY) common stock performance before fees and expenses.

• Market capitalization stands at $0.00B, indicating its specialized and focused nature within the ETF market.
• Exhibits a Beta of 0.20, reflecting its distinct correlation profile, which is primarily inverse to its underlying asset, LLY.
• Does not pay a dividend, consistent with its design as a tactical trading instrument focused on capital appreciation from inverse movements.
• Utilizes a daily rebalancing strategy, meaning its investment objective is reset each day, which can lead to significant performance deviations over longer holding periods.

Who Are ELIS's Competitors?

ELIS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ELIS's Key Strengths?

Provides direct 1x inverse daily exposure to Eli Lilly (LLY), enabling targeted bearish plays.

• Offers an alternative to short selling LLY, potentially simplifying execution for some traders.
• Intra-day liquidity as an ETF, allowing for flexible entry and exit points.
• Clear and transparent investment objective for daily performance.

What Are ELIS's Weaknesses?

Significant risk of performance deviation from -1x LLY over periods longer than one day due to compounding.

• Not suitable for long-term holding; designed strictly for daily trading.
• Requires active monitoring and a deep understanding of inverse and leveraged ETF mechanics.
• Subject to tracking error, where the ETF's performance may not perfectly mirror its stated objective.

What Could Drive ELIS Stock Higher?

ELIS catalyst: Negative news or adverse developments related to Eli Lilly's (LLY) drug pipeline, clinical trials, or regulatory approvals, which could trigger a decline in LLY's stock price.

• Broader market downturns or sector-specific headwinds impacting the pharmaceutical industry, potentially leading to a bearish outlook on LLY.
• Release of Eli Lilly's quarterly earnings reports or significant corporate announcements that fall short of market expectations, prompting a negative reaction in LLY's share price.
• Major competitive advancements or new drug approvals by Eli Lilly's rivals that could threaten LLY's market share or future revenue streams.

What Are the Key Risks for ELIS?

Compounding Risk: The most significant risk is the effect of compounding over periods longer than one day.

• ELIS's daily objective means its performance over extended periods can deviate significantly from -100% of LLY's performance, potentially leading to substantial losses even if LLY's stock ultimately declines.
• Eli Lilly (LLY) Price Appreciation: If Eli Lilly's stock price consistently rises, ELIS will incur daily losses, leading to a rapid erosion of capital for investors holding the fund.
• Tracking Error: The ETF may not perfectly achieve its stated daily investment objective due to various factors, including transaction costs, market liquidity, and the performance of the derivatives used.
• Volatility Decay: In volatile markets where LLY's stock price fluctuates significantly without a clear trend, the daily rebalancing of ELIS can lead to a decay in value over time, even if LLY's net change over a period is small.
• Regulatory Scrutiny: Leveraged and inverse ETFs have faced increased regulatory attention in the past due to their complexity and risks. Future regulatory changes could impact the product's availability or structure.

What Are the Growth Opportunities for ELIS?

• Increased Bearish Sentiment on Eli Lilly: A significant and sustained increase in negative investor sentiment towards Eli Lilly and Company (LLY) could drive demand for inverse exposure products like ELIS. Factors such as clinical trial failures, regulatory setbacks for key drugs, or unexpected competitive pressures could lead to a bearish outlook on LLY. For instance, if LLY faces a major patent expiry without a robust pipeline replacement, or if a competitor introduces a superior drug, investors might seek to profit from a potential decline in LLY's stock. This would increase trading volume and assets under management for ELIS, particularly for short-term tactical plays.
• Market Volatility and Macroeconomic Headwinds: Periods of heightened market volatility or broader macroeconomic uncertainty can lead investors to seek hedging instruments or opportunities to profit from declining asset prices. If the overall market experiences a downturn, or if the pharmaceutical sector specifically faces headwinds such as increased pricing scrutiny or reduced R&D funding, LLY's stock could be negatively impacted. ELIS provides a direct, albeit short-term, way to capitalize on such sector-specific or market-wide bearish trends, attracting traders looking to navigate turbulent conditions.
• Expansion of Single-Stock Leveraged/Inverse ETF Market: The broader market for single-stock leveraged and inverse ETFs is a relatively new and evolving segment. As investors become more familiar with these products and their specific use cases for tactical trading, the overall demand for such specialized instruments could grow. Increased education and liquidity in this market segment could lead to more widespread adoption of products like ELIS, as traders seek precise tools to express high-conviction views on individual equities without traditional short-selling complexities.
• Strategic Hedging by Institutional Investors: While primarily a retail trading tool, institutional investors or hedge funds with long positions in Eli Lilly (LLY) might utilize ELIS for short-term hedging purposes. Instead of selling a portion of their LLY holdings or engaging in complex options strategies, they could use ELIS to temporarily offset potential daily losses during periods of anticipated negative news or market corrections specific to LLY. This strategic use case, even if for short durations, could contribute to consistent demand and trading activity for the ETF.
• Increased Awareness and Accessibility of Inverse Products: As financial platforms and brokerages continue to democratize access to a wider range of investment products, increased awareness and easier accessibility of inverse ETFs could drive growth. Educational initiatives explaining the mechanics and risks of daily rebalancing, coupled with user-friendly trading interfaces, could encourage more sophisticated retail traders to incorporate ELIS into their short-term strategies, especially when they hold a strong bearish conviction on Eli Lilly.

What Threats Does ELIS Face?

• Sustained bullish performance of Eli Lilly (LLY) stock, leading to consistent losses for the fund.
• Regulatory scrutiny or restrictions on leveraged and inverse ETFs.
• Lack of investor understanding leading to misuse and significant losses, potentially harming product reputation.
• Competition from other inverse products or more traditional short-selling strategies.

What Are ELIS's Competitive Advantages?

• Specialized Product Offering: Provides highly specific 1x inverse daily exposure to a single, prominent stock (LLY), catering to a niche demand that might not be easily replicated by generic inverse market ETFs.
• Brand Recognition (Direxion): Benefits from Direxion's established brand as a leading provider of leveraged and inverse ETFs, which lends credibility and familiarity to the product.
• Liquidity and Accessibility: As an ETF, it offers intra-day liquidity and ease of trading through standard brokerage accounts, making it more accessible than complex derivative strategies for some investors.
• Operational Expertise: Direxion possesses the operational expertise and infrastructure required to manage the daily rebalancing and derivative contracts necessary to achieve the fund's stated objective.

What Does ELIS Do?

The Direxion Daily LLY Bear 1X ETF (ELIS) is an exchange-traded fund designed to provide inverse daily exposure to the common stock performance of Eli Lilly and Company (LLY). Specifically, ELIS aims to achieve daily returns that mirror the opposite movement of LLY's share price, by a factor of 100%, before accounting for any associated fees and expenses. This means that if LLY's stock price declines by 1% on a given day, ELIS is designed to increase by approximately 1% on that same day, and vice versa. As a product of Direxion, a prominent provider of leveraged and inverse ETFs, ELIS caters to investors seeking to capitalize on short-term declines in Eli Lilly's stock. It is crucial to understand that ELIS is structured for daily performance objectives. Its investment goal is reset each day, meaning that its performance over periods longer than one day may deviate significantly from -100% of LLY's performance due to the effects of compounding. This characteristic makes ELIS a highly specialized tool, primarily suited for sophisticated investors with a short-term trading horizon who actively monitor the underlying asset, Eli Lilly. The ETF's market position is intrinsically linked to the performance and investor sentiment surrounding Eli Lilly, a global pharmaceutical giant. ELIS operates within the broader asset management industry, offering a distinct product that allows for tactical plays against a specific large-cap stock. Its existence alongside a counterpart, the Direxion Daily LLY Bull 2X ETF, which seeks to double (200%) the direct daily performance of LLY shares, highlights Direxion's strategy of providing both bullish and bearish leveraged/inverse options for individual stocks. This dual offering underscores the demand for tools that enable investors to express high-conviction, short-term views on specific company performances. The fund's headquarters are in New York, US, reflecting its integration into the global financial services landscape.

What Products and Services Does ELIS Offer?

• Provides an investment vehicle that moves in the opposite direction of Eli Lilly and Company (LLY) stock on a daily basis.
• Aims to achieve daily returns that are -100% of LLY's daily performance, before fees and expenses.
• Functions as an Exchange Traded Fund (ETF), trading on stock exchanges like regular shares.
• Designed for short-term trading strategies, typically for a single day.
• Allows investors to potentially profit from a decline in Eli Lilly's share price without directly short selling.
• Part of a family of Direxion ETFs that offer leveraged and inverse exposure to various underlying assets.

How Does ELIS Make Money?

• Charges a management fee (expense ratio) to investors for managing the fund and its underlying derivatives.
• Generates revenue from the assets under management (AUM) through these recurring fees.
• Utilizes financial derivatives (e.g., swaps, futures) to achieve its inverse daily objective, incurring associated trading costs which are passed on to the fund.
• Benefits from increased trading volume, which can lead to higher liquidity and potentially tighter bid-ask spreads, although direct revenue from trading volume is not typically a primary income source for the fund itself.

What Industry Does ELIS Operate In?

Direxion Daily LLY Bear 1X ETF operates within the Financial Services sector, specifically under the Asset Management industry. This segment of the financial market is characterized by firms that manage investment portfolios and funds, including specialized products like exchange-traded funds (ETFs). ELIS represents a niche but growing area within asset management: inverse and leveraged ETFs. These products cater to sophisticated investors and traders who seek to amplify returns or hedge against specific market movements over very short time horizons. The broader trend in the asset management industry includes a diversification of product offerings, moving beyond traditional mutual funds to include passive index funds, smart beta ETFs, and actively managed ETFs, alongside specialized instruments like ELIS. The competitive landscape for such targeted, inverse single-stock ETFs involves other providers of similar leveraged/inverse products, although direct competitors offering 1x inverse exposure to LLY specifically might be limited. ELIS's position is defined by its direct inverse correlation to Eli Lilly, making its market demand directly tied to sentiment and outlook for that particular pharmaceutical company.

Who Are ELIS's Key Customers?

• Sophisticated individual traders seeking to express short-term bearish views on Eli Lilly (LLY).
• Active investors looking for tactical instruments to capitalize on anticipated daily declines in LLY's stock.
• Traders who prefer an ETF structure for inverse exposure over traditional short selling.
• Investors who understand the complexities and risks associated with daily rebalancing and compounding effects in inverse ETFs.

Direxion Daily LLY Bear 1X ETF (ELIS) Valuation Context

Valued at $3.84M, ELIS is classified as a micro-cap stock.

Return on equity for Direxion Daily LLY Bear 1X ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. ELIS trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

ELIS Financials

ELIS Latest News

No recent news available for ELIS.

Direxion Daily LLY Bear 1X ETF Financial Services Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources